<DOC>
	<DOCNO>NCT01036854</DOCNO>
	<brief_summary>The objective study assess blood level ondansetron ( EUR1025 24 mg ) dose Zofran 8 mg dose single multiple dos give take meal take empty stomach .</brief_summary>
	<brief_title>Pharmacokinetic Study Ondansetron Administered IR ( Zofran ) MR ( EUR1025 )</brief_title>
	<detailed_description>The objective study evaluate pharmacokinetics ( PK ) ondansetron administer novel modified-release formulation ( EUR1025 24 mg ) well immediate-release formulation ( Zofran 8 mg ) single multiple oral dose administration fast feed condition base requirement respective indication . The safety profile treatment also assess record nature , severity , frequency , duration relation treatment adverse event .</detailed_description>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>Male female volunteer Non exsmokers At least 21 year age old 55 year Body mass index target least 18.5 less 30 kg/m2 . Acceptable lab test Normal 12 lead ECG Negative human chorionic gonadotropin ( hCG ) female . No known hypersensitivity Ondansetron relate product No presence significant gastrointestinal , liver kidney disease , condition know interfere absorption No presence significant heart disease disorder discover screen ECG Not pregnant No alcohol drug abuse history No use enzymemodifying drug , include strong inhibitor cytochrome P450 ( CYP ) No previous Investigational Product ( another clinical trial ) donate 50 ml blood previous 28 day day 1 study</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ondansetron , EUR-1025</keyword>
</DOC>